Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRD | O14764 | 1/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.64 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.64 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.64 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.64 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.64 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10293551 | 0.94 | GABRD (0.64) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL12017808 | 0.93 | GABRD (0.71) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL9362932 | 0.93 | GABRD (0.71) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL16574186 | 0.89 | GABRD (0.66) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL3583338 | 0.86 | HPGD (0.73) | SIGMAR1HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL1753628 | 0.84 | HPGD (0.76) | HPGDALDH1A1PKMKMT2AMEN1 | |
| SCHEMBL10192065 | 0.84 | ALDH1A1 (0.71) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL8358137 | 0.84 | SIGMAR1 (0.81) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL14466291 | 0.84 | SIGMAR1 (0.60) | SIGMAR1HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL3063116 | 0.84 | SIGMAR1 (0.60) | SIGMAR1HPGDALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241554-B1 | QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | AGIOS PHARMACEUTICALS INC (US) | 2020-01-29 | — | — | EP | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2012059932-A1 | 2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-10 | — | — | WO | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | GABRD 1304/4885GABRA1 1791/4885GABRB1 1612/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | GABRD 4080/4885GABRA1 3943/4885GABRB1 3037/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | GABRD 2860/4885GABRA1 3597/4885GABRB1 1679/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | GABRD 2860/4885GABRA1 3597/4885GABRB1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.